Patent intelligence · US
US 11844841
Dosing regimens and related compositions and methods
Dosing regimens and related compositions and methods
Patent details — US 11844841
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 19, 2023
- Expiration
- Dec 14, 2043
- Applicant
- Apellis Pharmaceuticals, Inc.
- Claims
- 26
- CPC classes
- A61K, A61K38/00, A61K47/60, A61K47/643
Quick answer
US 11844841 (Dosing regimens and related compositions and methods) is held by Apellis Pharmaceuticals, Inc.. Status: granted. Granted Dec 19, 2023. Expires Dec 14, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Apellis Pharmaceuticals, Inc.
- Grant date
- Expiration
- Claims
- 26
- CPC classes
- A61K, A61K38/00, A61K47/60, A61K47/643, A61K47/6901, A61K9/0019
More from Apellis Pharmaceuticals, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12290566
Dosing regimens and related compositions and methods
granted -
US 12251395
RNAS for complement inhibition
granted -
US 11903994
Dosing regimens
granted -
US 11712460
Methods of treating chronic disorders with complement inhibitors
granted -
US 11661441
Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof
granted -
US 11510939
RNAs for complement inhibition
granted -
US 11407789
Cell-penetrating compstatin analogs and uses thereof
granted
Frequently asked questions
What is US patent 11844841?
US 11844841 (Dosing regimens and related compositions and methods) is held by Apellis Pharmaceuticals, Inc.. Status: granted. Granted Dec 19, 2023. Expires Dec 14, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11844841?
Apellis Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 24 pharmaceutical patents for this assignee.
When does US 11844841 expire?
Our index shows an expiration date of Dec 14, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.